Abstract 614P
Background
Programmed Death Ligand-1 (PD-L1) is expressed in most type of cancer cells, including osteosarcoma. However, the role of PD-L1 expression in prognosis of osteosarcoma patients remains unclear. Thus, this study aims to investigate the association between PD-L1 expression and prognosis of Osteosarcoma patients.
Methods
Data was gathered from PubMed, PMC, and ScienceDirect databases on September 08, 2022, using keywords associated with PD-L1, Osteosarcoma in relation to the prognosis, which is measured by overall survival (OS), progression free survival (PFS), and event free survival (EFS). Publications included are associated with Osteosarcoma patients that are limited to English manuscripts within the last 10 years. Review articles, publications without full paper, and case report studies are excluded. The quality of each included study was assessed using the Newcastle Ottawa Scale (NOS), JBI Critical Appraisal for Quasi Experimental Studies, and Grading of recommendations, assessment, development, and evaluations (GRADE).
Results
A total of 7 studies consisting of 289 Osteosarcoma patients were included. All 6 studies have good quality based on NOS and one study categorized as include based on JBI. All 7 studies showed that high expression of PD-L1 correlates with poor prognosis of Osteosarcoma patients. Pooled analysis showed that high PD-L1 expression correlates with inferior OS (HR=2.03; 95%CI, 1.12-3.69; p=0.02) and PFS (HR= 1.18; 95%CI, 1.06-1.31; p=0.003). However, no significant association between PD-L1 expression and EFS (HR=1.05; 95%CI, 0.40-2.75; p=0.92). Based on GRADE, the result of this study is moderate in quality, as there is no inconsistency in results and publication biases are minimal.
Conclusions
Current studies demonstrated that high PD-L1 expression is associated with inferior OS and PFS, but not EFS in osteosarcoma patients, which warrants further prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract